US District Court decides that Vectura's US patent 8303991 was found valid and infringed by US sales of three of GSK Ellipta products.

Vectura Group plc confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura's US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline's (GSK) Ellipta products. The jury awarded Vectura $89.7 million in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of these products.

Vectura expects to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021. The jury also found that GSK's infringement was willful. The willfulness finding gives Vectura the right to seek enhanced damages. GSK has the option to appeal the decision.